Becton Dickinson & Co Stock Price, News & Analysis

BD (NYSE: BDX) celebrates 55 years of manufacturing at its Sumter, South Carolina facility on Oct. 3, 2025. The site began in 1970 with 25 employees and now spans >600,000 square feet, employs ~900 associates and produces billions of products annually, including BD Vacutainer® blood collection products that the company says care for 84 patients every second.

Since FY21, BD invested more than $90 million in Sumter, tripled year-over-year investment from FY24 to FY25, and plans to invest ~$30 million in FY26 for modernization, new lines and training. BD announced a $10,000 donation to the Tuomey Foundation and contributes >$100,000 annually to local organizations. BD operates >30 U.S. manufacturing and distribution sites across 17 states and Puerto Rico, employing >10,000 people.

BD (NYSE: BDX) has announced a groundbreaking pharmacy automation partnership with Henry Ford Health to revolutionize medication storage and prescription delivery. The collaboration centers on implementing the BD Rowa™ Vmax, a sophisticated pharmacy automation robot, across Henry Ford Health's hospital-based community pharmacies in Southeast and Central Michigan.

The partnership will enable 24/7 prescription access for patients and features automated high-capacity storage for safe and accurate prescription retrieval. This innovative system, already widely used in Europe, will allow pharmacy staff to focus on higher-value patient care tasks while improving operational efficiency. The implementation includes capabilities for real-time prescription tracking and can accommodate refrigerated medications, supplies, and over-the-counter products.

BD (NYSE: BDX) announced a significant milestone with the placement of its 1,000th BD Rhapsody™ System at Addenbrooke's Hospital of the University of Cambridge. The BD Rhapsody™ System, launched in 2017, is a leading single-cell multiomics analysis platform that has been cited in over 700 peer-reviewed publications.

The system enables researchers to analyze multiomic data from hundreds of thousands of single cells simultaneously, offering DNA, RNA, and protein analysis capabilities. The latest version, released in 2023, features enhanced sample processing and cell capture technology. BD is expanding the platform's capabilities with new launches, including the BD OMICS-One™ WTA Next Assay for early-access customers and the upcoming BD® OMICS-Guard Cryo for sample preservation.

BD (NYSE: BDX) has launched the Love Your Limbs™ PAD Community Screening Initiative to combat Peripheral Artery Disease (PAD), a circulatory disorder affecting over 21 million Americans and 200 million people globally. The initiative offers free ankle-brachial index screenings in partnership with physicians to detect PAD early.

The company is developing a PAD Health Access Dashboard and Heatmap to identify high-need communities and is partnering with organizations like Ochsner Health and The Way to My Heart. BD is also supporting the American Heart Association's National PAD Action Plan to increase awareness and improve early diagnosis of PAD, which causes over 150,000 preventable amputations annually in the U.S.

BD (NYSE:BDX), a leading global medical technology company, has announced its participation in the upcoming Wells Fargo 2025 Healthcare Conference. The company's presentation is scheduled for Wednesday, September 3, 2025, at 8:00 a.m. Eastern Time.

Investors and interested parties can access the live webcast of the presentation through BD's investor relations website at investors.bd.com. A replay will be made available on the same platform after the event concludes.

BD (NYSE:BDX) reported strong Q3 fiscal 2025 results with revenue reaching $5.5 billion, up 10.4% as reported and 3.0% organic. The company delivered significant earnings growth with adjusted diluted EPS of $3.68, up 5.1%. Notably, BD raised its full-year adjusted EPS guidance to $14.30-$14.45, reflecting 9.4% growth at the midpoint.

Key segment performance included BD Medical growing 14.4%, BD Life Sciences declining 0.5%, and BD Interventional increasing 7.2%. The company announced plans to combine its Biosciences & Diagnostic Solutions business with Waters Corporation and expects to complete the remaining $250 million of its $1 billion share buyback by fiscal year-end.

Gross margin improved significantly, with GAAP margin up 160 basis points and adjusted margin up 50 basis points, driven by BD Excellence initiatives. The company maintained its organic revenue growth guidance of 3.0-3.5% for fiscal 2025.

BD (NYSE: BDX), a leading medical technology company, has achieved a significant milestone as its Urology and Critical Care (UCC) and Surgery business units became the first in the medical technology industry to receive the diamond-level rating across all seven supply chain resilience domains from the Healthcare Industry Resilience Collaborative (HIRC).

The achievement follows a rigorous audit process evaluating multiple areas including demand planning, supplier management, inventory management, logistics, supply chain visibility, risk management, and operational health. This recognition builds upon BD's previous Transparency Partner Badge received in 2023 and reflects the company's ongoing investments in supply chain and manufacturing operations improvements.

BD (NYSE: BDX) has announced a $35 million investment to expand its prefilled flush syringe manufacturing capacity at its Columbus, Nebraska facility. The expansion will create approximately 50 new jobs and increase production of BD® PosiFlush™ Prefilled Flush Syringes by hundreds of millions of units annually.

The company has already invested over $80 million in the past three years, increasing U.S. production by more than 750 million units, including a 10% increase this year. This investment is part of BD's larger $2.5 billion commitment to enhance U.S. manufacturing capacity over the next five years.

The Columbus facility, operating for over 75 years, is the largest manufacturer of prefilled flush devices in the U.S. BD currently operates more than 30 U.S. manufacturing and distribution facilities across 17 states and Puerto Rico, employing over 10,000 people.

BD (NYSE: BDX) has submitted an FDA application for a groundbreaking at-home HPV testing solution that could revolutionize cervical cancer screening. The innovative system combines a user-friendly self-collection swab with advanced laboratory robotics through the BD COR™ System.

The technology detects more high-risk HPV strains than any other available test and features a convenient self-collection process that eliminates the need for in-office gynecological visits. According to a Harris Poll survey, 72% of U.S. women have delayed gynecology visits, while 81% desire more comfortable testing options. The BD Onclarity™ Assay has been included in ASCCP's Enduring Risk-Based Management Guidelines, and self-collection testing is currently under consideration in USPSTF draft recommendations.